<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00734955</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00007857</org_study_id>
    <secondary_id>1R01EB011574-01A1</secondary_id>
    <nct_id>NCT00734955</nct_id>
  </id_info>
  <brief_title>An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients</brief_title>
  <official_title>An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Biomedical Imaging and Bioengineering (NIBIB)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our objective is to develop a novel optical assay system for intra operative assessment of
      tumor margins in partial mastectomy or mastectomy specimens. Our group has previously shown
      that optical techniques can effectively discriminate between malignant and non-malignant
      breast tissues. We have also shown that data collection and processing from a single point on
      the tissue specimen requires less than 5 seconds. In addition, the technique is easily
      adaptable to provide sensing depths that are required for breast margin assessment. The goal
      of the work proposed in this protocol is to test the sensitivity and specificity of an
      optical assay system developed by our group, for intra operative assessment of breast tumor
      margins.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of the optical signatures of breast tissue.</measure>
    <time_frame>Day of procedure</time_frame>
    <description>The primary outcome measure of this study is to identify the optical signatures of normal and cancerous tissue.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">485</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Reduction Mammoplasty</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing reduction mammoplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mastectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing mastectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lumpectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing a lumpectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>49-channel optical spectrometer</intervention_name>
    <arm_group_label>Lumpectomy</arm_group_label>
    <arm_group_label>Mastectomy</arm_group_label>
    <arm_group_label>Reduction Mammoplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Breast Cancer

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nimmi Ramanujam, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 13, 2008</study_first_submitted>
  <study_first_submitted_qc>August 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Partial Mastectomy</keyword>
  <keyword>Lumpectomy</keyword>
  <keyword>Mastectomy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

